Minoryx Therapeutics has made a significant step forward in its bid to get lead candidate leriglitazone on the market with EU regulators accepting a file for the drug as a potential treatment for the devastating rare orphan disease, X-linked adrenoleukodystrophy (X-ALD).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?